Shanghai Runda Medical Technology Co., Ltd.

XSSC:603108 Stock Report

Market Cap: CN¥10.2b

Shanghai Runda Medical Technology Valuation

Is 603108 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 603108 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 603108 (CN¥16.95) is trading below our estimate of fair value (CN¥72.37)

Significantly Below Fair Value: 603108 is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 603108?

Other financial metrics that can be useful for relative valuation.

603108 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2x
Enterprise Value/EBITDA20.8x
PEG Ratio2.7x

Price to Sales Ratio vs Peers

How does 603108's PS Ratio compare to its peers?

The above table shows the PS ratio for 603108 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.3x
300463 Maccura BiotechnologyLtd
3.1x13.2%CN¥8.5b
603127 Joinn Laboratories(China)Co.Ltd
6.1x13.3%CN¥11.8b
688046 GemPharmatech
8.1x20.9%CN¥5.6b
301333 R&G PharmaStudies
7.8x18.8%CN¥5.8b
603108 Shanghai Runda Medical Technology
1.2xn/aCN¥10.2b

Price-To-Sales vs Peers: 603108 is good value based on its Price-To-Sales Ratio (1.2x) compared to the peer average (6.3x).


Price to Earnings Ratio vs Industry

How does 603108's PE Ratio compare vs other companies in the CN Life Sciences Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a31.4%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a31.4%
n/an/an/a
No more companies

Price-To-Sales vs Industry: 603108 is good value based on its Price-To-Sales Ratio (1.2x) compared to the CN Life Sciences industry average (4.8x).


Price to Sales Ratio vs Fair Ratio

What is 603108's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

603108 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.2x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 603108's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies